Sanofi
Biopharmaceutical company selling medicines, vaccines and consumer health products.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Sanofi S.A.
- Entity type
- COMPANY
- Headquarters
- 46, avenue de la Grande Armée, 75017 Paris
- Company size
- >5,000
- Market role
- Other / Non-Digital Advertising Relevant
- Ticker
- SNY
- Official website
- sanofi.com
What Sanofi does
Sanofi creates value by investing in R&D, developing regulated therapies and vaccines, securing approvals, manufacturing at scale and distributing products through healthcare and retail channels. Its revenue base combines prescription product sales, vaccine sales, consumer healthcare sales and selective licensing or partnership income, with value concentration in branded and differentiated assets supported by global commercial infrastructure.
Category differentiation
Sanofi is a pharmaceutical and vaccines manufacturer, not an adtech, martech or software platform vendor. Its content properties support corporate communication and consumer health discovery rather than constituting its core revenue engine.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Sanofi S.A. is a public biopharmaceutical company headquartered in France. It discovers, develops and commercialises prescription medicines and vaccines, and it also operates a consumer healthcare division under the Opella brand. The company serves healthcare systems, providers, pharmacies, distributors, patients and consumers across multiple markets through regulated pharmaceutical and consumer health channels.
Company news briefing
Briefing updated:
Sanofi continues to advance its strategic partnership with Cheplapharm focused on mature medicines to optimise the commercialisation of established pharmaceutical portfolios. Additionally, the company has filed its latest 6-K financial report with the SEC, detailing ongoing corporate and financial updates.
Business model & monetisation
Sanofi monetises through product sales of prescription medicines, vaccines and over-the-counter consumer healthcare products, supplemented by licensing and partnership arrangements. Commercial pricing is shaped by patent protection, regulatory frameworks, negotiated reimbursement and retail pharmacy sell-through, rather than software subscriptions or advertising.
- Prescription medicines
- Branded and reimbursed product sales
- Vaccines
- Institutional and healthcare channel product sales
- Consumer healthcare
- Retail and pharmacy OTC product sales via Opella
- Licensing and partnerships
- Licensing, collaboration and related commercial agreements
Products & capabilities
No products with linked sources are available in this view.
Products & market categories
Media Channel
Technology
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
6-K Financial Filing Analysis for Sanofi (2026-09-17)
financials · Recorded impact score: 3.4/5
On September 17, 2026, Sanofi submitted a Form 6-K filing with the U.S. Securities and Exchange Commission incorporating a press release dated September 14, 2026. The filing announces a new strategic partnership between Sanofi and Cheplapharm focused on mature medicines. This partnership reflects Sanofi's ongoing portfolio optimization strategy, allowing the company to streamline operations, monetize or efficiently manage established pharmaceutical assets, and reallocate focus and capital toward core growth drivers and innovative pipeline therapies.
- Sanofi entered into a strategic partnership with Cheplapharm focused on its mature medicines portfolio, originally announced via press release on September 14, 2026.
- The Form 6-K regulatory submission was formally executed and signed on September 17, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.
Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Recorded impact score: 4/5
Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Agentic AI Transforming Pharma Marketing for Rare Diseases
AI · Recorded impact score: 3/5
This article discusses how agentic AI is poised to revolutionize pharmaceutical marketing, particularly for rare disease treatments. With traditional drug development costing $2.6 billion and taking 12-15 years, AI is compressing discovery timelines and enabling treatments for smaller patient populations, with rare disease approvals now exceeding 50% of FDA approvals. However, this precision medicine creates a marketing challenge: reaching small, specific audiences efficiently. The article argues that while programmatic advertising optimized campaign execution, agentic AI can synthesize vast healthcare, audience, and market data to provide actionable commercial insights, forecast patient need, and continuously adapt strategies. Early tests show marketing planning cycles collapsing by up to 10x. This approach aims to make more treatments commercially viable, improving treatment economics and driving further investment.
- The pharma industry invests $2.6 billion on average to bring a new treatment to market, taking 12 to 15 years with a 10% success rate.
- Rare disease approvals now account for over 50% of FDA drug approvals, up from below 30% a decade ago.
Even World-Class CMOs Struggle to Find New Roles
Marketing Workforce · Recorded impact score: 2/5
Mark Ritson writes that outgoing General Mills CMO Valentina Ciobanu, despite a strong track record, is struggling to find a new senior marketing role, highlighting a broader contraction in the CMO job market. General Mills removed its regional leadership layer for Europe, Australia and North Asia, eliminating her role. Ritson cites data showing US marketing employment remains about 27% below pre-pandemic levels and that fewer Fortune 500 companies have CMOs on their executive teams. LinkedIn reports applicants per US job opening have doubled since spring 2022, while the American quit rate has fallen to 2%, indicating senior marketers are staying put. He argues AI is driving consolidation of marketing organizations, reducing leadership roles and changing CMOs' duties toward evaluating AI-generated work. Ciobanu will be available from January and is seeking B2C CMO roles in London or elsewhere.
- General Mills removed the regional leadership layer for Europe, Australia and North Asia from September, eliminating Valentina Ciobanu's regional CMO role.
- US marketing employment remains around 27% below pre-pandemic levels, according to the American Marketing Association's 2026 careers report.
Explore company relationships
Questions about Sanofi
What is Sanofi?
Sanofi is a public biopharmaceutical company that develops and sells medicines, vaccines and consumer healthcare products.
Who uses Sanofi?
Healthcare systems, hospitals, physicians, pharmacies, distributors, patients and OTC consumers use Sanofi products and information services.
How does Sanofi make money?
Sanofi makes money from prescription medicine sales, vaccine sales, OTC consumer health sales and selected licensing or partnership income.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
10 publicly documented primary sources and citations linked across the market graph.
Continue your research on Sanofi
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.